Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. [2] . The drug was developed by …

2020年7月2日 · Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K (v) 7.2-7.5) ion channels defines RTG/EZG as the first neuronal potassium (K …

Retigabine (N - [2-amino-4- (4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester) is a unique antiepileptic compound that was identified during screening at the National Institutes of Health …

瑞替加滨具有潜在的神经保护作用，它可以永久性减少 大脑中动脉 闭塞的梗死面积，可以逆转单侧颈动脉闭塞导致的功能缺失。 1.瑞替加滨为 神经元 [4] 开放剂，是一种具有全新作用机制的 …

2012年1月5日 · In this article, we consider the pharmacologic characteristics of RTG/EZG at the receptor, cellular, and network levels as a means of understanding the novel and efficacious …

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. …

2011年9月30日 · Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) …

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. …

Retigabine (INN; USAN ezogabine) is an anticonvulsant with a novel mechanism of action, which activates voltage-gated potassium channels of the Kv7 subfamily [265R].

2012年8月29日 · Retigabine is indicated in the EU [8] and US [9] as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy. This article reviews the …